Doxorubicin Recruiting Phase 2 Trials for Progesterone Receptor Negative / Triple-Negative Breast Cancer (TNBC) / Progesterone Receptor-negative Breast Cancer / Estrogen Receptor Positive / Stage IIA Breast Cancer / Triple-Negative Breast Carcinoma / Her2-Positive Breast Cancer / Progesterone Receptor Positive / HER2/Neu Positive / Estrogen Receptor-negative Breast Cancer / Stage IA Breast Cancer / Stage II Breast Cancer / Stage III Breast Cancer / HER2/Neu Negative / Progesterone Receptor-positive Breast Cancer / Invasive Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIA Breast Cancer / Estrogen Receptor Negative / Stage IIB Breast Cancer / Stage IIIC Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02315196Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
NCT01750073Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer
NCT03933319Phase Ⅱ Study of Pegylated Liposomal Doxorubicin(PLD)Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer